product name Isotretinoin
Description: Isotretinoin (also known as 13-cis retinoic acid) was developed to be used as a chemotherapeutic medication for the treatment of brain cancer, pancreatic cancer etc. Isotretinoin directly interferes with the development of cranial neural crest cells. Isotretinoin selectively affects neural crest cells by decreasing their cell-substratum adhesion. Isotretinoin (500 ng/mL) and its main metabolite in the human, 4-oxo-isotretinoin, induce malformations similar to those seen in vivo.
References: J Craniofac Genet Dev Biol. 1986;6(3):211-22; Dev Biol. 1987 Sep;123(1):276-81; Pharmacol Biochem Behav. 2008 Dec;91(2):243-51.
300.44
Formula
C20H28O2
CAS No.
4759-48-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 60 mg/mL (199.7 mM)
Water: <1 mg/mL
Ethanol: 1 mg/mL (3.32 mM)
Solubility (In vivo)
Synonyms
13-cis retinoic acid
other peoduct :
| In Vitro |
In vitro activity: Isotretinoin directly interferes with the development of cranial neural crest cells. Isotretinoin selectively affects neural crest cells by decreasing their cell-substratum adhesion. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Isotretinoin (500 ng/mL) and its main metabolite in the human, 4-oxo-isotretinoin, induce malformations similar to those seen in vivo. Isotretinoin impairs explicit memory in Stage 2, but retention tests one month after Isotretinoin exposure ended, indicated recovery from this explicit memory impairment and evidence of enhanced implicit memory in the 10 mg and 15 mg ISO rats. Isotretinoin slows the recovery of rod signaling after exposure to an intense bleaching light, and that rhodopsin regeneration is markedly slowed. Isotretinoin is also found to protect rat photoreceptors from light-induced damage. Isotretinoin blocks the formation of A2E biochemically and the accumulation of lipofuscin pigments by electron microscopy. Isotretinoin also blocks the slower, age-dependent accumulation of lipofuscin in wild-type mice. |
| Animal model | |
| Formulation & Dosage | |
| References | J Craniofac Genet Dev Biol. 1986;6(3):211-22; Dev Biol. 1987 Sep;123(1):276-81; Pharmacol Biochem Behav. 2008 Dec;91(2):243-51. |
